Stock Research for IBB

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

IBB Stock Chart & Research Data

The IBB chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the IBB chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


IBB Due diligence Resources & Stock Charts

The IBB stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View IBB Detailed Price Forecast - CNN Money CNN View IBB Detailed Summary - Google Finance
Yahoo View IBB Detailed Summary - Yahoo! Finance Zacks View IBB Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View IBB Trends & Analysis - Trade-Ideas Barrons View IBB Major Holders - Barrons
NASDAQ View IBB Call Transcripts - NASDAQ Seeking View IBB Breaking News & Analysis - Seeking Alpha
Spotlight View IBB Annual Report - CompanySpotlight.com OTC Report View IBB OTC Short Report - OTCShortReport.com
TradeKing View IBB Fundamentals - TradeKing Charts View IBB SEC Filings - Bar Chart
WSJ View Historical Prices for IBB - The WSJ Morningstar View Performance/Total Return for IBB - Morningstar
MarketWatch View the Analyst Estimates for IBB - MarketWatch CNBC View the Earnings History for IBB - CNBC
StockMarketWatch View the IBB Earnings - StockMarketWatch MacroAxis View IBB Buy or Sell Recommendations - MacroAxis
Bullish View the IBB Bullish Patterns - American Bulls Short Pains View IBB Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View IBB Stock Mentions - StockTwits PennyStocks View IBB Stock Mentions - PennyStockTweets
Twitter View IBB Stock Mentions - Twitter Invest Hub View IBB Investment Forum News - Investor Hub
Yahoo View IBB Stock Mentions - Yahoo! Message Board Seeking Alpha View IBB Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for IBB - SECform4.com Insider Cow View Insider Transactions for IBB - Insider Cow
CNBC View IBB Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for IBB - OTC Markets
Yahoo View Insider Transactions for IBB - Yahoo! Finance NASDAQ View Institutional Holdings for IBB - NASDAQ


Stock Charts

FinViz View IBB Stock Insight & Charts - FinViz.com StockCharts View IBB Investment Charts - StockCharts.com
BarChart View IBB Stock Overview & Charts - BarChart Trading View View IBB User Generated Charts - Trading View




Latest Financial News for IBB


Biotech Sector Could Enter Bear Market
Posted on Friday October 19, 2018

Biotech price action at all capitalization levels has deteriorated in recent weeks, with the two major sector funds giving up the majority of their 2018 gains. The iShares Nasdaq Biotechnology Index Fund ( IBB) and the SPDR S&P Biotech ETF ( XBI) carve different price patterns due to their unique holdings and construction. The market-cap weighted Nasdaq fund is dependent upon its biggest components, with Amgen Inc. ( AMGN), Gilead Sciences, Inc. ( GILD), Biogen Inc. ( BGEN) and Celgene Corporation ( CELG) comprising more than 32% of portfolio weighting.


Analyzing Biogen before Its Third-Quarter Earnings
Posted on Friday October 19, 2018

Biogen (BIIB), a leading biotechnology company, is scheduled to release its third-quarter earnings on October 23. Analysts expect the adjusted EPS to be $6.78 on revenues of $3.33 billion during the third quarter.


Merrimack Pharmaceuticals' stock plummets toward record low after cancer drug trial terminated
Posted on Friday October 19, 2018

Shares of Merrimack Pharmaceuticals Inc. plummeted 35% toward a record low in premarket trade Friday, after the biopharmaceutical company said it terminated a phase 2 trial of its non-small cell lung cancer treatment after it failed to improve progression free survival. "Since futility was observed, the decision was made to terminate the study," the company said in a statement. Merrimack said it is implementing a review of its drug candidate pipeline, and will provide an update on its Nov. 7 conference call following third-quarter results. The stock had tumbled 50% year to date through Thursday, while the iShares Nasdaq Biotechnology ETF had gained 5.8% and the S&P 500 had tacked on 3.6%.


Equillium's stock opens 2.5% above IPO price
Posted on Friday October 12, 2018

Shares of Equillium rose in their public debut, as they opened 2.5% above the initial public offering price. The first trade was at $14.35 at 11:12 a.m. Eastern for 130,085 shares. The stock edged higher since to be up 4.3%. The IPO priced late Thursday at $14, at the bottom of the expected range of $14 to $16, to value the biotechnology company at about $233.8 million. Equillium sold 4.67 million shares to raise about $65.4 million. The company went public at a time that the Renaissance IPO ETF has dropped 11.6% over the past three months, the IShares Nasdaq Biotechnology ETF has shed 5.8% and the S&P 500 has slipped 1.1%.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.